VOR
$13.72
Vor Biopharma Inc.
Recent News
Getty Images, Torm, and More Stocks See Action From Activist Investors
Activists also report to the SEC on Vor Biopharma, Camp4 Therapeutics, and Recursion Pharmaceuticals.
Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed?
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate telitacicept. JPMorgan’s initiation of coverage, citing telitacicept as highly de-risked across multiple indications, underscores how external validation is shaping investor perception of Vor’s pipeline. With the shares rising meaningfully over the past week, we’ll examine how telitacicept’s Phase 3...
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term commercial opportunity. See our latest analysis for Vor Biopharma. Those telitacicept headlines have clearly reset expectations, with a 1 day share price return of 28.23 percent and a 7 day share price return of 25.97 percent at 10.72 dollars. However, the 1 year total shareholder return is still down...
Is There An Opportunity With Vor Biopharma Inc.'s (NASDAQ:VOR) 49% Undervaluation?
Key Insights Vor Biopharma's estimated fair value is US$15.10 based on 2 Stage Free Cash Flow to Equity Vor Biopharma...
Vor Bio assumed with a Neutral at Wedbush
Wedbush analyst Martin Fan assumed coverage of Vor Bio (VOR) with a Neutral rating with a price target of $9, up from 40c. The firm notes Vor’s lead candidate telitacicept is a BAFF/APRIL ligand trap approved in China for systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis. Wedbush sees read-through to all development indications should telitacicept yield comparable efficacy to leading MG and SjD candidates in global trials. However, considering the company’s reliance on a